See more : Nordea Invest Global Small Cap (NDIGSCKL1.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Eupraxia Pharmaceuticals Inc. (EPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eupraxia Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Scotch Creek Ventures Inc. (SCVFF) Income Statement Analysis – Financial Results
- China International Capital Corporation Limited (3908.HK) Income Statement Analysis – Financial Results
- The Goldman Sachs Group, Inc. (GOS.DE) Income Statement Analysis – Financial Results
- Challenger Energy Group PLC (CEG.L) Income Statement Analysis – Financial Results
- Namchow Holdings Co., Ltd. (1702.TW) Income Statement Analysis – Financial Results
Eupraxia Pharmaceuticals Inc. (EPRX)
Industry: Biotechnology
Sector: Healthcare
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 209.91K | 193.27K | 111.53K | 116.81K | 201.94K | 125.83K | 85.38K |
| Gross Profit | -209.91K | -193.27K | -111.53K | -116.81K | -201.94K | -125.83K | -85.38K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 27.54M | 17.20M | 9.68M | 859.78K | 2.94M | 6.64M | 3.19M |
| General & Administrative | 9.65M | 5.81M | 8.89M | 1.27M | 3.01M | 7.54M | 1.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.65M | 5.81M | 8.89M | 1.27M | 3.01M | 7.54M | 1.70M |
| Other Expenses | 0.00 | 0.00 | -2.26M | 0.00 | 1.74K | 0.00 | 0.00 |
| Operating Expenses | 37.92M | 23.20M | 18.68M | 2.25M | 6.16M | 14.31M | 4.97M |
| Cost & Expenses | 37.92M | 23.20M | 18.68M | 2.25M | 6.16M | 14.31M | 4.97M |
| Interest Income | 407.04K | 569.32K | 65.73K | 427.00 | 12.04K | 1.11K | 330.00 |
| Interest Expense | 1.58M | 1.59M | 1.30M | 1.88M | 1.46M | 142.17K | 52.81K |
| Depreciation & Amortization | 209.91K | 193.27K | 111.53K | 116.81K | 201.94K | 125.83K | 85.38K |
| EBITDA | -36.75M | -22.14M | -21.96M | -2.01M | -5.94M | -14.57M | -4.89M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.90M | -22.63M | -20.87M | -2.25M | -6.15M | -14.31M | -4.97M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.29M | -64.07K | -5.46M | -1.76M | -1.08M | -2.95M | -143.13K |
| Income Before Tax | -39.18M | -23.92M | -23.37M | -4.01M | -7.24M | -14.83M | -5.00M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -89.67K | 930.52K | -1.34M | 1.87M | 1.40M | -1.46M | -627.56K |
| Net Income | -37.39M | -23.26M | -22.99M | -4.00M | -7.18M | -13.23M | -4.32M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| EPS Diluted | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| Weighted Avg Shares Out | 24.15M | 19.29M | 14.24M | 12.87M | 12.87M | 12.87M | 12.87M |
| Weighted Avg Shares Out (Dil) | 24.15M | 19.29M | 14.24M | 12.87M | 12.87M | 12.87M | 12.87M |
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
DiffuSphere™ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing systemic drug levels to optimize safety In clinical trials, a single administration of DiffuSphere™ successfully delivered fluticasone propionate for at least...
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
VICTORIA, BC , Nov. 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence Registration for the webinar now open to the public by visiting EPRXNOV1524.TribePublic.com VICTORIA,...
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12...
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
VICTORIA, BC , Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced...
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
VICTORIA, BC , Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased...
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
VICTORIA, BC , Oct. 28, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that...
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Publication of Eupraxia's Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR. As outlined in Lancet Rheumatology, Eupraxia's EP-104IAR imparts clinically significant and durable pain relief, while also having minimal changes in glucose and cortisol,...
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
VICTORIA, BC , Oct. 10, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that...
Eupraxia Pharmaceuticals Strengthens Senior Management Team
VICTORIA, BC , Oct. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the...
Source: https://incomestatements.info
Category: Stock Reports